Natalizumab in Crohn's disease

Results from a US tertiary inflammatory bowel disease center

Atsushi Sakuraba, Kian Keyashian, Chase Correia, John Melek, Russell D. Cohen, Stephen B. Hanauer, David T. Rubin

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Natalizumab is an efficacious agent for the induction and maintenance of remission in patients with Crohn's disease (CD) who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center. Methods: Retrospective case review of patients with CD receiving natalizumab. Results: Forty-nine patients with CD (28 women; median age, 33 years) receiving natalizumab from April 2008 to November 2011 were identified. Median duration of disease was 180 months (range, 36-576 months); 40 patients had ileocolonic disease, 1 had ileal disease, and 8 had colonic disease. Twenty-one patients had penetrating disease, and 28 had a history of CD-related surgical treatment. Forty-seven patients previously failed treatment with at least 1 anti-TNF agent. Median duration of natalizumab treatment was 7 months (interquartile range, 3-21.5 months). Twenty-four patients (49%) were continuing natalizumab at the time of this review, and 25 discontinued treatment because of the lack of response, side effects, or positive JC virus antibody. Seventeen patients (35%) successfully continued treatment with natalizumab for longer than 12 months, and nonpenetrating disease phenotype was identified as a predictor of longer response (compared with penetrating phenotype; P = 0.013). Nine patients (18.4%) experienced adverse effects, 5 of which were serious, but no case of progressive multifocal leukoencephalopathy occurred. Conclusions: This is the largest series of natalizumab-treated patients with CD. Our results show that natalizumab is an efficacious and safe treatment agent for patients refractory to anti-TNF agents and that nonpenetrating disease phenotype has more durable response over time.

Original languageEnglish (US)
Pages (from-to)621-626
Number of pages6
JournalInflammatory Bowel Diseases
Volume19
Issue number3
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Inflammatory Bowel Diseases
Crohn Disease
Tumor Necrosis Factor-alpha
Phenotype
Therapeutics
Ileal Diseases
Natalizumab
Colonic Diseases
JC Virus
Progressive Multifocal Leukoencephalopathy
Remission Induction
Proxy
Maintenance
Clinical Trials
Safety
Antibodies

Keywords

  • Biologic
  • Crohn's disease
  • Natalizumab
  • Safety

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Sakuraba, A., Keyashian, K., Correia, C., Melek, J., Cohen, R. D., Hanauer, S. B., & Rubin, D. T. (2013). Natalizumab in Crohn's disease: Results from a US tertiary inflammatory bowel disease center. Inflammatory Bowel Diseases, 19(3), 621-626. https://doi.org/10.1097/MIB.0b013e31827eea78

Natalizumab in Crohn's disease : Results from a US tertiary inflammatory bowel disease center. / Sakuraba, Atsushi; Keyashian, Kian; Correia, Chase; Melek, John; Cohen, Russell D.; Hanauer, Stephen B.; Rubin, David T.

In: Inflammatory Bowel Diseases, Vol. 19, No. 3, 03.2013, p. 621-626.

Research output: Contribution to journalArticle

Sakuraba, A, Keyashian, K, Correia, C, Melek, J, Cohen, RD, Hanauer, SB & Rubin, DT 2013, 'Natalizumab in Crohn's disease: Results from a US tertiary inflammatory bowel disease center', Inflammatory Bowel Diseases, vol. 19, no. 3, pp. 621-626. https://doi.org/10.1097/MIB.0b013e31827eea78
Sakuraba, Atsushi ; Keyashian, Kian ; Correia, Chase ; Melek, John ; Cohen, Russell D. ; Hanauer, Stephen B. ; Rubin, David T. / Natalizumab in Crohn's disease : Results from a US tertiary inflammatory bowel disease center. In: Inflammatory Bowel Diseases. 2013 ; Vol. 19, No. 3. pp. 621-626.
@article{900a3f65ca8e4ca1833572bdd616eb08,
title = "Natalizumab in Crohn's disease: Results from a US tertiary inflammatory bowel disease center",
abstract = "Background: Natalizumab is an efficacious agent for the induction and maintenance of remission in patients with Crohn's disease (CD) who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center. Methods: Retrospective case review of patients with CD receiving natalizumab. Results: Forty-nine patients with CD (28 women; median age, 33 years) receiving natalizumab from April 2008 to November 2011 were identified. Median duration of disease was 180 months (range, 36-576 months); 40 patients had ileocolonic disease, 1 had ileal disease, and 8 had colonic disease. Twenty-one patients had penetrating disease, and 28 had a history of CD-related surgical treatment. Forty-seven patients previously failed treatment with at least 1 anti-TNF agent. Median duration of natalizumab treatment was 7 months (interquartile range, 3-21.5 months). Twenty-four patients (49{\%}) were continuing natalizumab at the time of this review, and 25 discontinued treatment because of the lack of response, side effects, or positive JC virus antibody. Seventeen patients (35{\%}) successfully continued treatment with natalizumab for longer than 12 months, and nonpenetrating disease phenotype was identified as a predictor of longer response (compared with penetrating phenotype; P = 0.013). Nine patients (18.4{\%}) experienced adverse effects, 5 of which were serious, but no case of progressive multifocal leukoencephalopathy occurred. Conclusions: This is the largest series of natalizumab-treated patients with CD. Our results show that natalizumab is an efficacious and safe treatment agent for patients refractory to anti-TNF agents and that nonpenetrating disease phenotype has more durable response over time.",
keywords = "Biologic, Crohn's disease, Natalizumab, Safety",
author = "Atsushi Sakuraba and Kian Keyashian and Chase Correia and John Melek and Cohen, {Russell D.} and Hanauer, {Stephen B.} and Rubin, {David T.}",
year = "2013",
month = "3",
doi = "10.1097/MIB.0b013e31827eea78",
language = "English (US)",
volume = "19",
pages = "621--626",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Natalizumab in Crohn's disease

T2 - Results from a US tertiary inflammatory bowel disease center

AU - Sakuraba, Atsushi

AU - Keyashian, Kian

AU - Correia, Chase

AU - Melek, John

AU - Cohen, Russell D.

AU - Hanauer, Stephen B.

AU - Rubin, David T.

PY - 2013/3

Y1 - 2013/3

N2 - Background: Natalizumab is an efficacious agent for the induction and maintenance of remission in patients with Crohn's disease (CD) who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center. Methods: Retrospective case review of patients with CD receiving natalizumab. Results: Forty-nine patients with CD (28 women; median age, 33 years) receiving natalizumab from April 2008 to November 2011 were identified. Median duration of disease was 180 months (range, 36-576 months); 40 patients had ileocolonic disease, 1 had ileal disease, and 8 had colonic disease. Twenty-one patients had penetrating disease, and 28 had a history of CD-related surgical treatment. Forty-seven patients previously failed treatment with at least 1 anti-TNF agent. Median duration of natalizumab treatment was 7 months (interquartile range, 3-21.5 months). Twenty-four patients (49%) were continuing natalizumab at the time of this review, and 25 discontinued treatment because of the lack of response, side effects, or positive JC virus antibody. Seventeen patients (35%) successfully continued treatment with natalizumab for longer than 12 months, and nonpenetrating disease phenotype was identified as a predictor of longer response (compared with penetrating phenotype; P = 0.013). Nine patients (18.4%) experienced adverse effects, 5 of which were serious, but no case of progressive multifocal leukoencephalopathy occurred. Conclusions: This is the largest series of natalizumab-treated patients with CD. Our results show that natalizumab is an efficacious and safe treatment agent for patients refractory to anti-TNF agents and that nonpenetrating disease phenotype has more durable response over time.

AB - Background: Natalizumab is an efficacious agent for the induction and maintenance of remission in patients with Crohn's disease (CD) who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center. Methods: Retrospective case review of patients with CD receiving natalizumab. Results: Forty-nine patients with CD (28 women; median age, 33 years) receiving natalizumab from April 2008 to November 2011 were identified. Median duration of disease was 180 months (range, 36-576 months); 40 patients had ileocolonic disease, 1 had ileal disease, and 8 had colonic disease. Twenty-one patients had penetrating disease, and 28 had a history of CD-related surgical treatment. Forty-seven patients previously failed treatment with at least 1 anti-TNF agent. Median duration of natalizumab treatment was 7 months (interquartile range, 3-21.5 months). Twenty-four patients (49%) were continuing natalizumab at the time of this review, and 25 discontinued treatment because of the lack of response, side effects, or positive JC virus antibody. Seventeen patients (35%) successfully continued treatment with natalizumab for longer than 12 months, and nonpenetrating disease phenotype was identified as a predictor of longer response (compared with penetrating phenotype; P = 0.013). Nine patients (18.4%) experienced adverse effects, 5 of which were serious, but no case of progressive multifocal leukoencephalopathy occurred. Conclusions: This is the largest series of natalizumab-treated patients with CD. Our results show that natalizumab is an efficacious and safe treatment agent for patients refractory to anti-TNF agents and that nonpenetrating disease phenotype has more durable response over time.

KW - Biologic

KW - Crohn's disease

KW - Natalizumab

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84876360872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876360872&partnerID=8YFLogxK

U2 - 10.1097/MIB.0b013e31827eea78

DO - 10.1097/MIB.0b013e31827eea78

M3 - Article

VL - 19

SP - 621

EP - 626

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 3

ER -